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Abstract
Background: The present permanent deferral policy in Israel for MSM was established in 1977 and was based on
the previous (now outdated) USA Food and Drug Administration standards. This study analyses epidemiological
data regarding blood donations among MSM, in order to estimate the risk for HIV transfusion transmitted infection
(TTI) if the policy is changed to allow at-risk MSM to donate blood.
Methods: An Excel based spreadsheet model integrated demographic, epidemiological data from the HIV National
Register, laboratory, blood donation and testing data in order to calculate TTI due to false-negatives in known HIV+
donors, windows period donations, asymptomatic carriers and laboratory misclassification errors. A sensitivity
analysis of our estimated TTIs for deferral periods for MSM was performed based on a literature review regarding
this overall policy issue worldwide.
Results: MSM in Israel have a considerably higher relative risk (RR) of both prevalence (115) and incidence (143) of
being HIV+ than persons without a risk factor. Allowing MSM to donate blood, without any deferral period, will add
an additional five HIV TTI cases over the next decade. Imposition of a 1 or 5 years deferral of abstinence will
increase the number of HIV TTI cases only by 0.10 and 0.05 cases, respectively.
Conclusion: A 1 year deferral period for blood donations from MSM in Israel is recommended.
Keywords: HIV, Men having Sex with Men, Transfusion Transmitted Infection, Blood Donations
Background
There is an ongoing debate worldwide regarding per-
manent versus temporal deferral and receiving blood
donations from persons with defined high risk behavior
[1, 2], such as men who have sex with men (MSM) [3, 4].
The rationale and the benefits of such deferral/exclusion
for MSM [5–10] have been questioned by lesbian, gay,
bisexual, and transgender advocacy organizations seeking
to change the current policy, in the light of technological
advances in screening using Nucleic Acid Testing. This
testing method enables a higher detection rate of contami-
nated blood by improving the tests sensitivity for the
detection of causative agents of Transfusion Transmitted
Infection (TTI) such as Human Immunodeficiency Virus
(HIV), Hepatitis B (HBV) or Hepatitis C (HCV) and by
reducing the length of the Window Period, during which
detection is impossible [11, 12]. Injection drug users
(IDU) are additional persons with defined high risk
behavior for TTI with those viruses [13, 14].
In addition the Israeli population is composed of immi-
grants from 142 countries, as well as work seekers, some
originate from specific countries with a Generalized HIV
Epidemic, like Ethiopia. Due to high prevalence and inci-
dence of mostly HIV and HBV, they are currently not
allowed to donate blood. Although this was changed in
april 2016 shortly after this papers acceptance.
The main reason for considering liberalizing blood do-
nation policy for MSM is a response to the lesbian, gay, bi-
sexual, and transgender advocacy organizations. The
reason is not demand driven, since blood supply shortages
are almost non-existent and the expected addition contri-
bution if all MSM were allowed to donate is only around
1.5% of the blood supply. Any shortages can be made up
by blood drives in the general not at-risk population.
Throughout the years since HIV detection, most coun-
tries have imposed an indefinite deferral period on
MSM. However, since the introduction of Nucleic Acid
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Testing, some countries have instituted a permanent 1
years’ deferral period for MSM who wish to donate blood,
with Canada allowing donations after a 5 years period of
abstinence [15]. In December 2015 the US Food and Drug
Administration announced its revised recommendations
that changed the donor deferral policy for MSM to a 1-
year deferral from last sexual contact [16]. In countries
where MSM are not permanently deferred the sexual risk
is assessed during the individual interview, conducted by a
physician or nurse, at the blood donation site [17].
The present permanent deferral policy of MSM since
1977, of the Ministry of Health in Israel, was based on the
previous (now outdated) FDA standards, and is reflected
in the Donor Health Questionnaire and the personal inter-
view, which are part of the screening process to potential
blood donors. The questionnaire gives potential donors an
option to self-defer from donating blood if they practice
high risk sexual behavior (including MSM or receiving
payment for sex), intravenous and non-prescribed drug
usage or originating from countries with high prevalence
and incidence of HIV, since 1977. The current deferral is
permanent since 1977.
Every blood donation in Israel is tested for the detection
of HIV-1, HIV-2, HBV, HCV and HTLV by chemilumines-
cent Immunoassay assay (ChlIA third generation, Prism,
Abbott) and by an Individual NAT testing for HIV-1,
HBV and HCV (Procleix Ultrio Assay, Grifols). Blood
donation criteria and guidelines are continuously reviewed
by the Advisory Committee to the Ministry of Health for
Transfusion Medicine.
The current article combines demographic, epidemio-
logical and laboratory data on MSM (and IDU) in order to
calculate their relative risks (RR) of being HIV positive in
addition to modeling an estimate of the absolute risk of HIV
TTI as a result of enabling them to donate blood. This work
was presented as evidence to an ad hoc committee nomi-
nated by the Director General of the Ministry of Health in
early 2014 to examine blood donor policies in Israel.
Methods
Incidence and population data
HIV data from the Department of Tuberculosis and AIDS
of the Ministry of Health, for the period 2005–2011, were
integrated with population data from the Central Bureau of
Statistics [18] in order to calculate incidence and prevalence
rates among Israeli MSM aged 18–69 (the permitted age
for blood donors) at high risk for HIV. These were com-
pared with HIV incidence and prevalence rates among
Israeli citizens who are not at high risk for HIV (ie: not
MSM, IDU or Originating in countries with a Generalized
Epidemic). The number of MSM of blood donation age
(around 68,000) was based on a locally accepted estimate
that 3% of males were MSM. Persons who were both MSM
and IDU were excluded from the MSM group. The number
of IDU was estimated to be 20,000 (Personal Communica-
tion: The Israeli anti-Drug Addiction Authority).
Spreadsheet modeling
An Excel based spreadsheet model was used to integrate
the demographic, epidemiological and laboratory data,
together with data on blood donations and testing from
the national Israeli Magen David Adom Blood Services
(MDABS), in order to calculate the expected number of
HIV positive cases that could be induced when changing
the current deferral policy.
Transmission pathways
We estimated the number of HIV transmissions from
screened blood donations that could occur by the follow-
ing four pathways (Table 1 lists the formulae for the calcu-
lations in detail):
Table 1 Calculation of magnitude of Transmission Pathways
The total expected number of transmission acquired HIV cases is
= BLOOD x T x (A + B + C + D)
Where A is the number of infected donors, who donate despite
knowing they are HIV+
A = POP x PREV x INFDON x (1-(1-((1-SNAT) x (1-SEIA))))
Where B is the number of infected donors during the windows period
where neither the Nucleic Acid Test nor ELISA test can detect HIV.
B = PSC x WNAT/(365.25 x YRSPS)
PSC = POP x INC x YRSPS x DON
Where C is the number of infected donors, who were asymptomatic
and were not detected due to false-negative screening results resulting
from the period where only the Nucleic Acid Test (but not the ELISA)
can detect HIV (C1) and the period where both NAT and ELISA can
detect HIV (C2).
C = C1 + C2
C1 = PSC x (1-SNAT) *(WNAT-WEIA)/(365.25 x YRSPS))
C2 = PSC x (YRSPS-WEIA/365.25)/YRSPS x (1-SNAT) x (1-SEIA)
Where D is the number of infected donors who are correctly detected
but whose blood nevertheless is allowed to be donated due to
laboratory misclassification errors.
D = (PSC + (POP x PREV x INFDON)- 2 (A + B + C)) x LAB
BLOOD = the average number of persons who become infected via
transfusions from a single infected donor
T = Probability that recipient of infected blood donation will become
infected (%)
POP = numbers aged 18–69 in group.
DON = Percentage of people in group who donate blood (%)
INFDON = Percentage of people who know they are HIV+ but
nevertheless donate.
PREV = Prevalence rate
INC = Incidence rate per annum
YRSPS = Pre-symptomatic period: average length of time from infection
to symptoms (years) based on weighted average of first-time to repeat
donors over the 10 year period
PSC = Number of pre-symptomatic donors
B1 = number of infected donors during the window period of the
Nucleic Acid Test.
B2 = number of infected donors during period when the Nucleic Acid
Test is working but EIS is still in window period
SNAT = Sensitivity of the Nucleic Acid Test
WNAT = Duration of the Nucleic Acid Test window period (days)
SEIA = Sensitivity of the anti-HIV test
WEIA = Duration of the anti-HIV window period (days)
LAB = Laboratory misclassification error rate (%)
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a) False-negative screening results of people who knew
they were HIV+ but nevertheless decided to donate
blood.
b) Blood donated during the “Window Periods” for anti-
HIV antibodies testing of 15 days [1, 3, 19] (range
15–22 days [1]) and HIV Nucleic Acid Testing of
5.6 days [1, 11, 12] (range 5.0–6.2 days [1]).
c) False negative screening results (ChlIA or Nucleic
Acid Testing) from asymptomatic HIV cases, from
the end of the window period till the median time of
appearance of symptoms of 10 years [20]. These
estimates are based on the sensitivity of HIV NAT
testing of 0.9906 [12] (range 0.9761–0.9974) and
anti-HIV testing of 0.9990 [3, 21], giving a combined
sensitivity of 0.9999906.
d) Results of human error, such as misclassification in
the laboratory where positives were recorded as
negatives or where infected blood had not been
disposed of by mistake. We used a value of 0.026%
(range 0.007% [3] – 0.05% [22]) based on the
weighted average of three studies [3, 9, 22].
Donation rates
In persons of blood donation age, there was a higher rate
of overall donations among males than females (7.0% vs.
2.7% in females). We assumed that, if deselected, MSM
will donate blood at the propensity as their gender specific
counterparts in the population of people who are not a
member of any high risk group (ie: not MSM, IDU or Ori-
ginating in Countries with a Generalized HIV Epidemic).
Transfusion infections
We next estimated the number of people infected with
HIV from blood transfusions. According to data from
MDABS each whole blood unit donated in Israel is
divided to several components given to 2.5 persons on
average. Using a 92.5% transmission rate [23] we applied
the estimate that each contaminated donation will con-
taminate, on average, 2.31 persons.
Sensitivity analyses
In addition, we performed a sensitivity analysis on our
estimated TTIs based on the range of values (defined by
the maximum and minimum of each parameter) for the
test sensitivity, windows length, asymptomatic period
and misclassification parameters.
Effects of deferral
Since we did not have the necessary information to build
a complex dynamic transmission model for HIV, we
relied on estimates from the literature as to the effect of
different deferral periods on donations from MSM,
adjusted by the relative prevalence of MSM in the study
countries to the Israeli situation, where an estimated 3%
of males are MSM according to the advocacy groups of
the gay community.
The reported effects of a 1 year deferral were from
England and Wales with 3.5% MSM prevalence [3],
Canada 4.5% [24] and the USA 6.0% [9]. The USA
study [9] was supplemented by an additional study from
England and Wales with a 3.5% prevalence [25] in order
to estimate the effect of a 5 years deferral period. A further
paper from England was not included as it was based on
pre-Nucleic Acid Test detection technologies [26].
Results
Relative risks
MSM have considerably higher relative risks (RR) of
prevalence (x115) and incidence (x143) of being HIV+
than NHR persons in the Israeli population (Table 2).
Therefore, blood donors in Israel who are MSM are 115
times more likely to be infected with HIV+ than mem-
bers of a non-high risk group.
The higher RR of HIV prevalence among MSM is
reflected in the higher probabilities of a TTI resulting
from an undetected infected donation (1:9,328 dona-
tions) compared with 1: 2,094,286 donations from per-
sons not at a high risk of HIV (Table 3).
Estimation of TTI cases
Our model predicted that if Israel continues with the
current policy of only allowing members of NHR to
donate blood, then around 1.03 HIV+ cases (95% CI:
0.90–1.21) will be transmitted during the next decade.
The vast majority of these cases (96.1% or 0.99 cases)
would arise from undetectable cases during the Window
Period. A further 0.025 cases (2.4%) would arise from
misclassification errors, which have grown in relative im-
portance due to increasing sensitivity of tests and shorten-
ing of the windows detection periods [9]. An additional
0.016 cases (1.5%) will arise from false negative asymp-
tomatic post-window period donations, whilst the number
Table 2 Epidemiological data by risk behavior
MSMa IDUb No-Risk
Groupc
Population aged 18–69 in 2011 68,036 20,000 4,509,517
Prevalence HIV+ 1,244 632 714
Prevalence/100,000 aged 18-69 1,828 3,160 15.8
Relative Risk of HIV prevalence 115 200 1
Annual Incident Cases 126 44 58
Incidence/100,000 aged 18–69 (2005–2012) 185 222 1.3
Relative Risk of HIV incidence 143 171 1
Notes:
aassuming MSM prevalence of 3% among males
bMSM who are also IDU are classified under IDU
cRest of Population excluding Immigrants from countries with Generalized
HIV Epidemic
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of false-negative symptomatic transmissions from dona-
tion from persons who already know they are HIV+ is
negligible (Table 3).
Based on this data, allowing MSM to donate blood,
without any deferral period, is likely to increase the num-
ber of HIV+ TTI cases by 4.99 (95% CI: 4.30 – 5.88) over
the next decade, an almost six-fold increase in overall risk.
Effect of deferral on TTI cases
Adjusted estimates (for MSM prevalence) of additional
TTI in the case where MSM are allowed to donate blood
after 1 year of reported abstinence, ranged from 6.4%
[24] to 7.8% [3] to 15.7% [9] due to differences in param-
eters used in the three publications. Based on these esti-
mates, the number of additional HIV+ TTI cases in
Israel would increase by 0.10 (Range: 0.07–0.19) over a
decade or one TTI every hundred years.
For a 5 year deferral period, the adjusted (for MSM
prevalence) two estimates of the absolute increase in
TTI were 2.8% [9] and 6.3% [25]. Based on this range, if
policies were changed to allow MSM to donate blood
after a 5 year self-reported abstinence rate, the number
of HIV TTI would rise by around 0.05 (Range: 0.03–
0.08) cases over a decade or one TTI every 200 years.
Intravenous drug users
Just for comparison we performed a similar analysis of
data regarding IDU in Israel, assuming IDU reporting be-
havior is the same as MSMs. We estimate that there will
be 1.16 (95% CI: 1.01 –1.36) additional cases in the com-
ing 10 years if IDU are allowed to donate and no-deferral
is implemented, with 0.04 (Range 0.03–0.08) and 0.02
(0.01–0.03) additional cases if 1 or 5 years deferral from
last exposure will be applied, respectively (Tables 2 and 3).
Discussion
In view of the continuous pressure applied on decision
makers in Israel to change the current indefinite deferral
policy for MSM, we evaluated the additional risks of
HIV TTI, using a self-built mathematical model based
on inputs from the literature for scenarios where defer-
ral for either a 5 or 1 year period after last sexual rela-
tion, or no- deferral is adopted.
Based on the epidemiological data in Israel, allowing
MSM to donate blood, without any deferral period, will
increase the number of HIV TTI cases by 4.99 from 1.03
to 6.02 cases over the next decade. Imposition of 1 and
5 year deferral rules will increase the number of HIV
TTI cases among MSM by 0.10 (0.07–0.19) and 0.05
(0.03–0.08) cases respectively.
Unfortunately, it is impossible to predict future immi-
gration patterns into Israel, whether from countries with
high (e.g. Ethiopia) or low HIV prevalence (e.g. France)
so our model made no attempt to adjust for future
demographic changes among blood donors. Educational
materials for donors and blood collection teams will be
prepared ad-hoc, as required.
Our estimates of the number of TTI HIV cases are
biased downwards for two major reasons:
1. The real windows period for anti-HIV testing, which
accounts for some 77% of TTI cases in our model,
can be in fact much longer than the 15 days that we
used in our calculations. In fact, while these 15 days
count only for the end of the eclipse period, the
secoconversion period depends greatly on each
individual, and can continue for several weeks [27].
Therefore, it is well accepted and practiced that
when someone has a negative anti-HIV testing early
after a potential HIV exposure, she/he should per-
form an additional anti-HIV testing 6 to 12 weeks
after the exposure which was potentially at risk (and
even later in some cases) [27, 28].
2. Our static model did not include any estimates of
secondary transmissions generated by the initial
infected blood recipient [3, 29].
Advocates of allowing members of high risk groups to
donate blood use the following arguments:
a) There will be an increase in the blood supply which
will help other members of society.
b) Since the current probabilities of being infected by
blood transfusion are so absolutely low, the
assumption is that potential recipients (i.e.: everyone
in the society) do not see this as a risk. In economic
Table 3 Annual number of HIV+ TTI cases caused by blood
transfusions from different risk behavior during the next decade
MSM (a) IDU (b) No-Risk
Group (c)




FN PS 0.07 0.02 0.02
Misclassification 0.25 0.06 0.02
Total TTI 4.99 (4.30-5.88) 1.16 (1.01-1.36) 1.03 (0.90-1.21)
No. of Donors 4,659 1,108 216,601
One TTI for every 9,328 10,718 2,094,286
Donations
One year Deferral TTI
0.10 (0.07–0.19) 0.04 (0.03–0.08)
Five year Deferral TTI
0.05 (0.03–0.08) 0.02 (0.01–0.03)
Notes:
FN False - negative
PS Asymptomatic carriers
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jargon, there is a probabilistic threshold below which
the marginal disutility of taking the risk is zero.
Changing to a temporal deferral policy may improve the
reporting compliance of MSM who did not have sexual
relations for the past 1 or 5 years, and by doing so, may in
fact increase the safety of the blood donations. Many of
the 68,000 MSM, not all of whom are high risk, would
appreciate the change in policy and hence may be more
likely to comply better with the new deferral policy.
By doing so, the safety of the national blood inventory
might well increase. However one should notice that
although the additional risk of TTI HIV among other
people with risk behavior (i.e. about 20,000 IDU) is simi-
lar or even smaller (owing perhaps to their fewer num-
bers), no lobbies exist, to the best of our knowledge,
whether in Israel or worldwide, for introducing changes
in their permanent deferral policy.
The counter-arguments are:
a) The expected increase of blood donations of currently
deferred donors is negligible, adding only 2.1%, 1.0%
[3, 9] and 0.3% [9, 22] additional donors with no
deferral, 1 year and 5 years deferrals respectively.
b) In Israel, like in other developed countries, a Patient
Blood Management Program exists, causing a drop
in the usage of blood units and components [30, 31]
in times of peace. When an urgent need to increase
the national blood inventory arises, it can be
achieved by safer means such as increased
recruitment of members of the large population
group who are not at high risk, who have relatively
lower donation propensities.
c) Blood recipients in Israel (of a total population of
over 8,000,000 persons) have the right to as safe
a blood supply as possible. Hence they will be
“less happy” (or in economic jargon: lose utility)
if they perceive the blood supply as potentially
more dangerous as a result of allowing at-risk
groups to donate. A low-risk threshold does not
exist. Even if it did exist, in an ex- post retrospective
analysis one would have to take into account the
suffering (dis-utility) caused to a small number of
person, who will definitely be infected with HIV from
transfusions.
d) It is unethical to impose an additional risk for HIV
on any population group (especially when they have
not even been consulted) in order to decrease a
feeling of discontent in other people who are
currently considered to have higher risk, based on
epidemiological data.
e) Members of the non-risk-groups will feel good that
others in the population (altruistic externality) are
receiving as safe a blood supply as possible.
f ) Relaxing constraints totally on MSM and/or IDU
donations will cause an increase in HIV+ blood
donor related cases. Thus leading to the conclusion
that there would be more benefits to the public
from reducing the numbers of HIV+ MSM who
donate blood, than from increasing the numbers
of HIV+ MSM who may give blood [26].
While the AIDS-HIV registry enabled us to analyze rela-
tive risks for HIV by populations with risk behaviors, no
such registries exist in Israel for HBV or HCV infections.
Any change in policy needs to be accompanied by the
establishment of a national monitoring program, to track
rates of other infections (including other Transfusion-
Transmitted Diseases) in the general population in order
to assess risk factors in donors with HIV, HBV or HCV
infections, and to study and evaluate these changes.
In deciding policy relating to blood donations one has
to strike a balance between the safety of recipients, en-
suring an adequate blood supply as well as societal/legal
obligations to treat everyone fairly. Given that no trans-
fusion is risk free, the question is what degree of risk is
acceptable in order to meet the needs of recipients and
society [32].
Lack of homogeneity of results of reported deferral
periods caused us to just give a wide range of estimates
for the effects of deferral periods on MSM. A Canadian
study [24] reported that while the risk of implementing
a 1 year deferral policy for MSM is very low, it can never
be shown to be zero. They concluded that given today’s
paradigm in blood safety, even a miniscule risk incre-
ment would be unjustified and undesirable. Another
Canadian study reported that choosing a 1 year deferral
period for MSM would almost certainly give rise to an
incremental risk of TTI infection, and that such a policy
would represent an unethical type of risk transfer from
one social group to another, and would therefore be un-
acceptable [10]. Canada has since adapted a policy of
allowing MSM to donate blood, after 5 years of abstin-
ence, with a resultant worst-case estimate of one HIV
contaminated unit every 1,072 years [33].
It should be noted that modeling studies indicate that
adherence of potential blood donors to deferral policies
is of major relevance, suggesting that good donor com-
pliance may outweigh the negative effects on blood
safety postulated for changing from permanent to tem-
porary deferral periods for high risk sexual behaviors.
The fact that a considerable percentage of donors are
MSM - despite the permanent deferral policy [34] dem-
onstrates the need to increase donor education and un-
derstanding [17]. It should be emphasized that our
literature-based estimates of cases from MSM donors
under a deferral system are based on a conservative esti-
mate that does not take into account any possible gains
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resulting from less people giving false information about
their MSM status as a consequence of instituting an MSM
deferral period.
Whether or not to recommend the institution of a 1
year deferral period, as recommended lately by the FDA
for the USA [16], or a 5 year period as in Canada [33] can
be based on a value judgment as to whether or not 0.10 or
0.05 are subjectively acceptable increases in MSM TTI.
Based on the present model we recommend the insti-
tution of a 1 year deferral period for MSM to donate
blood in Israel. However, we are aware of the fact that
MSM are at a higher risk of other infections transmitted
by blood (including Hepatitis B and C) than heterosex-
ual men and women [13, 35, 36], so basing policy deci-
sions solely on risks of TTI from just HIV in isolation is
somewhat sub-optimal and inadequate. We therefore
recommend that the suggested change in policy be
accompanied by improving educational and other inter-
ventions with people with high risk behavior, upgrading
the existing Nucleic Acid Testing and building a national
hemo-vigilance and TTI monitoring system that will
allow us to follow up the impact of such a policy change.
In addition, a recent publication from the USA showed
that noncompliance with the MSM policy is evident and
may be increasing compared to earlier data [37]. We join
the authors’ recommendations that any change from the
current policy requires close monitoring to determine
whether it affects residual risk of HIV in the Israeli
blood supply.
It should be also mentioned that there is an additional
option of using an additional Nucleic Acid Test, 2 weeks
post donation to the current Nucleic Acid Testing. If the
additional Nucleic Acid Testing is negative then the Whole
Blood unit which was held in quarantine can be released.
However, this double- Nucleic Acid Testing protocol was
considered to be unfeasible because of organizational con-
straints, stigmatization, loss of at least two major blood
components and possible cost-effectiveness issues.
In the light of the elevated RR found in people with
high risk behavior regarding HIV risks alone (as opposed
to considering in addition hepatitis risks), we strongly
recommend that if a change in the deferral policy for
MSM is adopted, it must however be accompanied by
the following steps:
1. Upgrading the current Nucleic Acid Test to a more
advanced test generation, to allow earlier detection
of HIV, HBV and HCV and the addition of HIV 2.
2. Implementing steps to improve education, attitude,
knowledge and compliance of potential donors with
high-risk behavior, with the deferral criteria.
3. Creating a national Hemo-vigilance program to
collect data on blood donors and recipients, to
monitor and ensure safer, best quality blood supply.
4. Finally, we recommend that any change in policy
should be brought to the knowledge of the public,
including analysis only. Ethical and societal issues are
obviously related to such decisions, which often involve
feelings of stigmatization and/or discrimination.
We note that the non-compliancy rate among MSM in
Israel (i.e. MSM donate blood despite the restriction on
accepting donations) is around 2.04% per annum, being
of similar magnitude to that of 1.8% reported in Canada
[38], 2.5% in the UK [39], 2.6% in the USA [37] and
4.5% in England [26]. Based on the UK and USA experi-
ences, adoption of a 1 year deferral for donations from
MSM is likely to reduce the non-compliancy rate by half
[37, 39]. Furthermore, a non-compliancy rate as low as
0.2% has been attained in Australia [40], under a 1 year
deferral regulation, by making the donors sign an exten-
sive legal declaration that they are not MSM before
donating.
Conclusion
A 1 year deferral period for blood donations from MSM
in Israel is recommended.
We trust that recommendation that is based on hard
data provides an appropriate balance to the public’s fear of
allowing more high risk people to donate and the percep-
tion of activist groups that they are being discriminated
against by the current lifetime MSM deferral.
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